February 23, 2022 7:39am
It ain’t over until the bottoms bounce
Pre-open indications: 8 BUY indications, 3 SELL indications and 1 pimp/pump/promote
RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.
Earnings Reporting (this week) Dates: Global Blood Therapeutics (GBT) – Wednesday, 2/23, Sage Therapeutics (SAGE), Thursday, 2/24, Ionis Pharmaceuticals (IONS) - Thursday, 2/24, Sangamo Therapeutics (SGMO) - Thursday, 2/24, Editas Medicine (EDIT) - Thursday, 2/24
Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.
Only the facts … I ask questions and note the indications
Dow futures are UP +0.53% (+179 points), S&P futures are UP +0.65% (+28 points) and NASDAQ futures are UP +1.05% (+146 points)
U.S. stock market futures were higher in pre-open trading Wednesday
European stocks moved higher as the “sabers rattled” and tanks rolled,
Asia-Pacific stocks rose recapturing lost upside, markets in Japan are closed today for a holiday.
Henry’omics:
Big earnings reporting week … with geopolitical military crisis volatility mixed-in … that could feed into inflationary pressures as energy costs will skyrocket
Yesterday, Tuesday, the Dow fell 483 points, or 1.42%, for its fourth straight negative session. At one point the 30-stock benchmark had been down more than 700 points.
The S&P 500 shed 1.01%, and is now 10.25% below its Jan. 3 record close, putting the broad market index in correction territory.
The Nasdaq declined 1.23% for its fourth straight negative session.
If you didn’t remember what happen at Tuesday’s close, you won’t be prepared for today’s session,
RegMed Investors’ (RMi) closing bell: “stuck in the penalty box. It could get worse until its better forget finding a bottom in the midst of chaos and uncertainty?” … https://www.regmedinvestors.com/articles/12311
Ebb and flow –
· February stats: 10 negative and 5 positive closes
· January stats: 1 holiday, 1 neutral, 13 negative and 6 positive closes
RegMed/Cell and Gene Therapy Earnings Scorecard Q4/21 and FY21 Results … https://www.regmedinvestors.com/articles/11628 ... AxoGen AXGN) added
The Biostage (OTC: QB: BSTG) Chronicles: Who, What, When, Where, Why and one H (HOW) … https://www.regmedinvestors.com/articles/12306
Companies in my headlights – It’s your decision; I provide ideas and context:
BUY on “bounce” pre-open indication …
AxoGen (AXGN -$0.13) +$0.23 or +3.17% after reporting Q4 & FY21
CRISPR Therapeutics (CRSP -$2.63) +$0.74 or +1.33%
Editas Medicine (EDIT -$0.19) +$0.49 or +3.26%
Intellia Therapeutics (NTLA -$2.33) +$0.82 or +0.97%
Vericel (VCEL -$1.62) +$0.73 or +2.19%
bluebird bio (BLUE -$0.02) +0.39 or +6.38%
Regenxbio (RGNX +$0.64) +$1.42 or +5.62%
uniQure NV (QURE $0.00) +0.14 or +0.87%
SELL on indication:
Fate Therapeutics (FATE $0.00) -$0.14 or -0.42% < reports Q4/FY21 next Monday
Global Blood Therapeutics (GBT -$1.30) -$0.22 or -0.70% <reports earnings today >
Sage Therapeutics (SAGE -$0.15) -$0.26 or -0.76% < reports earnings Thursday >
Pimp/Pump and Promote:
Biostage (OTCQB: BSTG) closed up on Tuesday +$0.62 with 4,225 shares out-of-nowhere after Friday’s -$0.68 to $3.88 with 103 shares traded after Thursday’s +$0.06 with 700 shares traded after Wednesday -$0.06 (had been -$0.98) with 420 shares traded, Tuesday’s flat with 200 shares traded and Monday’s flat with 1,899 shares traded
- WHO is BUYING these shares of a company with a 2-year-old IND, NO clinical trial initiation, a terminal death lawsuit overhang and a dwindling cash position?
- Also, by use of the pump/promote process; is BSTG preparing to register the outstanding private placement (PP) shares for a reverse to initiate an offering - they’re NOT going ANYWHERE without a cash inflow.
The BOTTOM LINE: The tanks have rolled, a “fait accompli” now let’s get some upside from the grossly oversold while the tanks just burned diesel.
To add to the chaos and uncertainty, this week has “heavy” earnings reporting
Earnings’ reporting:
· AxoGen AXGN) – Tuesday, 2/22
· Global Blood Therapeutics (GBT) – Wednesday, 2/23
· Sage Therapeutics (SAGE), Thursday, 2/24
· Ionis Pharmaceuticals (IONS) - Thursday, 2/24
· Sangamo Therapeutics (SGMO) - Thursday, 2/24
· Editas Medicine (EDIT) - Thursday, 2/24
· Fate Therapeutics, Monday, 2/28
· BioLife Solutions (BLFS), Monday,2/28
· Athersys (ATHX), Tuesday, 3/15
Investors should focus on forward-looking guidance, last year’s operating losses i.e., spending and cash positions or runways!
RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.
WHY do I keep reporting on Biostage (BSTG): I WAS there to experience what occurred and saw the decay of transparency and more; it takes courage, resolve and patience to stay the course of asking the questions without response!
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider their investment objectives.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in FATE, CRS, securities referred to in this publication.
